Sean N. Tucker, PhD

CSO, VP of Research
Vaxart
South San Francisco, California, United States

Disclosure information not submitted.

Presentation(s):

• 175 - An Open-Label Phase 1 Clinical Trial Demonstrating Improved Immune Responses to Norovirus Strains GI.1 and GII.4 from a Second Generation Oral Bivalent Vaccine Candidate

  Monday, October 20, 2025
  2:33 PM - 2:45 PM US ET